FBS0701 orphan drug status

Scrip    FerroKin secures $12 million for iron overload programme
Today
Peter Mansell

peter.mansell@talk21.com

US biotechnology company FerroKin BioSciences can step up development of its iron overload treatment, FBS0701, after securing additional funds through a $12 million financing.

FBS0701 is an orally available iron chelator that has orphan drug status for the treatment of transfusional iron overload

Aha

A few years ago there was about to come a new med on the market of tests with patients (not Exjade) but suddenly it was called back. You can wonder about wether or not this is it, but I think there are more farma's doing research into this.
I am glad you found it!